Objectives: Mycoplasma pneumoniae is a common aetiological agent of community-acquired respiratory tract infections for which macrolides are the treatment of choice. In France, only two macrolide-resistant isolates were reported in 1999. In contrast, several recent data reported that macrolide-resistant M. pneumoniae isolates have been spreading since 2000 in Japan. Mutations A2058G (Escherichia coli numbering), A2058C, A2059G, A2062G, C2611A and C2611G in domain V of the 23S rRNA gene were associated in vivo or in vitro with this resistance. The aim of this study was to determine whether macrolide resistance of M. pneumoniae is emerging in France.
Introduction
Mycoplasma pneumoniae causes respiratory tract infections and is responsible for up to 20% of all cases of community-acquired pneumonia, especially among school-aged children and young adults. 1, 2 Owing to the lack of sensitivity and to the prolonged time needed for M. pneumoniae detection by culture, molecular techniques are currently used for the diagnosis of M. pneumoniae infection. Tetracyclines, fluoroquinolones and macrolide, lincosamide, streptogramin and ketolide antibiotics (MLSKs) can be used for the treatment of M. pneumoniae infections. Macrolides are generally considered as the treatment of choice in both children and adults. 1 Very few M. pneumoniae macrolide-resistant isolates have been reported in the literature before 2000. 3 In Japan, several recent data reported that macrolide-resistant M. pneumoniae isolates have been spreading since 2000, with a prevalence increasing up to 30.6% according to the studies. 4 -8 In contrast, only two resistant isolates were reported in 1999 in France. 9 The A2058G mutation in domain V of 23S rRNA (Escherichia coli numbering) is the most frequent substitution associated with macrolide resistance in clinical isolates, followed by the A2059G mutation, while the A2058C and C2611G mutations are rare. 3 Moreover, we previously showed that the C2611A and A2062G mutations could be selected in vitro in the presence of different MLSKs. 10 Current methods to detect macrolide resistance in M. pneumoniae rely on time-consuming phenotypic or genotypic methods, such as susceptibility testing, restriction fragment length polymorphism (RFLP) 4 and 23S rRNA sequencing analysis. Recently, a real-time PCR and high-resolution melt (HRM) analysis-based technique has been developed to detect only the A2058G or A2059G mutation. 11 In order to determine whether macrolide resistance in M. pneumoniae was emerging in France, we developed a rapid method to detect all 23S rRNA mutations associated with macrolide resistance in M. pneumoniae, directly from clinical specimens. Two real-time PCR assays using fluorescent resonance energy transfer (FRET) with melting curve analysis were developed and applied on French clinical respiratory tract specimens.
Materials and methods

Bacterial strains and susceptibility testing
Two M. pneumoniae reference strains [M129 (ATCC 29342) and FH (ATCC 15531)] and 14 susceptible clinical isolates obtained from patients hospitalized at Pellegrin Hospital (Bordeaux, France) were used. Two French 9 and nine Japanese 4 erythromycin-resistant clinical isolates with characterized A2058G, A2059G, A2058C or C2611G mutations in the 23S rRNA gene were used. Moreover, eight Japanese in vitro-selected mutants 4, 8 harbouring the A2058G or the A2059G transition and five French in vitro-selected mutants 10 with the A2062G or the C2611A substitution were tested.
MICs of erythromycin and azithromycin were determined in Hayflick modified medium by an agar dilution method as previously described. 12 
Clinical samples
Twenty-one DNA extracts from Japanese respiratory tract clinical specimens infected with M. pneumoniae macrolide-resistant isolates harbouring the A2058G (n¼ 19) or the A2059G (n¼ 2) mutation were used to validate the real-time PCR assays. 6 We tested 142 respiratory tract samples, received between March 2007 and February 2008 at Pellegrin Hospital, for which the culture and in-house diagnostic real-time PCR targeting the M. pneumoniae adhesin P1 gene were negative. These samples were collected from patients with a negative M. pneumoniae serology. Moreover, 106 respiratory tract clinical samples, collected in the same hospital, with a positive M. pneumoniae detection by PCR, were tested. Among them, 39 samples, received between January 2005 and August 2008, yielded a M. pneumoniae isolate, for which erythromycin and azithromycin MICs were determined. The 67 other specimens, only M. pneumoniae PCR-positive, were systematically collected between July 1998 and August 2008.
DNA was extracted from clinical specimens or from bacterial cultures with the MagNA Pure LC kit (Roche, Meylan, France) according to the manufacturer's instructions.
Duplex real-time PCR
A duplex real-time PCR assay was performed on DNA extracted from M. pneumoniae strains and specimens to detect point mutations conferring resistance to macrolides. The method included duplex amplification of two fragments of the M. pneumoniae 23S rRNA gene with simultaneous hybridization of four probes and analysis of melting curves. Primers and probes specific for the M. pneumoniae 23S rRNA gene were designed after alignment of published 23S rRNA sequences from Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma penetrans, Ureaplasma parvum and Ureaplasma urealyticum. A basic local alignment search tool (BLAST) analysis of each primer and probe was performed and all organisms that had a significant BLAST hit were included in the analytical specificity assays (see below). Primers F1-Mpn and R1-Mpn (Table 1) Detection of M. pneumoniae macrolide resistance by PCR nucleotide. Two hybridization probe sets were designed for duplex analysis of the two mutation regions in the 23S rRNA gene. Each couple of probes included a sensor probe, 5 0 -labelled with LC-Red 640 or LC-Red 705, which hybridized to the region containing the mutation sites, and an anchor probe, fluorescein 3 0 -labelled, which hybridized to the three or four bases upstream from the former probe (Table 1) . Probes were obtained from Sigma-Aldrich (St-Quentin Fallavier, France).
The PCR and hybridization reactions were carried out in glass capillaries by using the LightCycler 1.5 thermocycler (Roche). Twenty microlitres of PCR mixture containing 2 mL of template DNA, 1.6 mL of 25 mM MgCl 2 , 1 mL of the four primers (5 mM each), 2 mL of the four probes (20 mM each) and 2 mL of FastStart DNA Master Hybridization Probes (Roche) was prepared. The cycling conditions consisted of an initial denaturation cycle at 958C for 10 min, followed by 50 amplification cycles (with a transition rate of 208C/s) consisting of 958C for 10 s, annealing at 588C for 20 s and extension at 728C for 20 s. After amplification a melting step was performed, consisting of 958C for 1 s, 358C for 40 s and followed by a slow rise in the temperature to 858C at a rate of 0.18C/s with continuous acquisition of fluorescence, with a final cooling step for 30 s at 408C. Data were analysed with the LightCycler software version 1.5 (Roche). The option 'polynomial' was selected for the calculation method for melting curve analysis and melting temperature (T m ) values were determined using the 'manual Tm'.
Identification of the A2058G mutation by simplex real-time PCR
An additional simplex real-time PCR assay was used to identify the A2058G mutation. Primers F1-Mpn and R1-Mpn were used with two hybridization probes, designed on the reverse strand of the M. pneumoniae 23S rRNA gene. The sensor probe, 3 0 -labelled with fluorescein, perfectly matched the 23S rRNA gene sequence harbouring the A-to-G transition at position 2058. The anchor probe was 5 0 -labelled with LC-Red 640 and 3 0 -phosphorylated (Table 1) . PCR mixture and amplification were performed as described above.
Sequencing analysis
Domain V of the 23S rRNA gene was amplified with primers MP23S-17b and MP23S-23 from strain or specimen DNA extracts. 10 Two fragments of interest in this domain were sequenced, one with primers MP23S-11 and MP23S-22 encompassing positions 2058, 2059 and 2062, and one with primers MP23S-9 and MP23S-23 encompassing position 2611. 10 
Specificity and limit of detection of the assays
To assess the specificity of the assays, DNA extracts from several Mycoplasma strains (M. genitalium, M. hominis, Mycoplasma fermentans, M. penetrans, Mycoplasma pulmonis, Mycoplasma amphoriforme, Mycoplasma orale, Mycoplasma salivarium, Mycoplasma pirum, Mycoplasma lipophilum and Mycoplasma faucium), Ureaplasma strains (U. urealyticum and U. parvum) and bacterial strains from the respiratory tract (E. coli, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus xylosus, Streptococcus anginosus, Streptococcus pneumoniae, Haemophilus influenzae, Enterococcus faecalis, Corynebacterium urealyticum, Neisseria perflava, Pseudomonas aeruginosa and Chlamydia pneumoniae) were used. In order to validate the efficiency of the extraction step, PCRs targeting the 16S rRNA genes were performed on each extract using primers F1-16S (CGTGTCGTGAGATGTTGGGTTA) and R1-16S (GACGTCATCCCCACCTTCCT) for non-mycoplasmal strains, and primers GPO3W (GGGAGCAAAYAGGATTAGATACC CT) and MGSO3W (GTTAACCTCCACTATRTTTCTATA) for mycoplasmal strains. To evaluate the detection limit of both assays, M. pneumoniae M129 DNA was extracted and amplified with each of the two primer sets F1-Mpn/R1-Mpn and F3-Mpn/R4-Mpn, respectively. Each amplified product was then purified using the Wizard w PCR Preps DNA purification system (Promega, Charbonnières, France) and subsequently cloned in the plasmid vector pGEM w -T Easy (Promega), according to the manufacturer's instructions. Plasmids pGEM-T MpnF1-R1 and pGEM-T MpnF3-R4 were transformed into E. coli and purified from the E. coli transformants using the Wizard w Plus SV Minipreps DNA Purification System (Promega). Purity and concentration of each plasmid DNA were determined by optical density measurements (NanoDrop 1000, Wilmington, USA). The detection limit of both PCRs assays was assessed by using 10-fold serial dilutions of plasmids pGEM-T MpnF1-R1 and MpnF3-R4.
Results
Detection of point mutations associated with macrolide resistance by duplex real-time PCR
A duplex real-time PCR assay was developed to detect point mutations conferring resistance to macrolides in the M. pneumoniae 23S rRNA gene. This assay, first evaluated on several genetically characterized M. pneumoniae strains, rapidly distinguished the 16 wild-type strains from those with a resistant genotype (24 strains). In the latter group, the existence of a nucleotide mismatch between the gene sequence and the hybridization probe produced a T m lower than the T m of the wild-type sequence. On the channel detecting the fluorescence emitted by LC-Red 640, melting curve analysis of DNA from control strains produced four different curves with T m s of 58.28C for the wildtype strains, 54.18C for mutants harbouring the A2058C or the A2062G substitution, 49.18C for mutants harbouring A2059G and 48.28C for mutants harbouring A2058G (Figure 1a) . Strains harbouring the C2611G or C2611A substitutions produced the same T m as the wild-type strains and were not detected here. On the second channel of the LightCycler, the LC-Red 705 fluorescence was measured. Two different melting curves were obtained, with T m s of 64.58C for the wild-type strains and 60.58C for mutants C2611G or C2611A (Figure 1b) . As expected, strains harbouring mutations at positions 2058, 2059 or 2062 had the same T m as the wild-type strains on this channel. It should be noted that an additional peak, weakly intense, which had a lower T m of 478C (Figure 1b) , was observed in the melting curve analysis detecting substitutions at position 2611, but had no consequence on the result interpretation.
Identification of the A2058G mutation by simplex real-time PCR
Differentiating the A2058G and A2059G mutation-related T m s could be difficult during the duplex real-time PCR assay. Consequently, we developed an additional simplex real-time PCR to detect specifically the A2058G mutation, which is the most frequent one. The sensor-probe1-2058G was designed to form a mismatch T:G with the wild-type sequence during hybridization. Therefore, the T m for the wild-type strain was lower than the one for the A2058G mutant, 60.28C versus 65.58C, respectively (Figure 1c) . It should be noted that melting peaks obtained with the A2058C, A2059G or A2062G substitutions could not be differentiated from that of the wild-type strain (Figure 1c ).
Specificity and limit of detection of the real-time PCR assays
With both real-time PCR assays, no amplification was observed with various mycoplasmal and non-mycoplasmal bacterial species, although all DNA extracts were amplified with the 16S rRNA PCRs. The detection limit of both the simplex and duplex PCR assays was 10 copies/mL for each probe set.
Patient specimen testing
The duplex real-time PCR was first validated by testing 21 DNA extracts from Japanese respiratory tract clinical specimens infected with a macrolide-resistant M. pneumoniae isolate, known to harbour the A2058G (n¼ 19) or the A2059G (n ¼ 2) mutation. 6 All DNA extracts were found to possess the expected substitution using the duplex real-time PCR assay. Moreover, the A2058G mutation was identified with the additional simplex real-time PCR in all the 19 DNA extracts known to harbour it. Using the duplex real-time PCR, 142 clinical samples for which no M. pneumoniae was detected by culture or by the in-house diagnostic real-time PCR remained negative.
Among 39 specimens for which both the diagnostic real-time PCR and culture were positive for M. pneumoniae, eight failed to amplify and 28 produced a melting peak characteristic of the wild-type genotype. These samples yielded M. pneumoniae isolates susceptible to erythromycin and azithromycin, as determined by MIC studies (data not shown). Three clinical specimens, named Mpn-3655, Mpn-3927 and Mpn-4276, collected in 2005 -06, were positive for resistance with the duplex real-time PCR. An A-to-G substitution, at position 2058 or 2059, was detected for the Mpn-3655 and Mpn-3927 specimens, according to the melting curve analysis (Table 2) . Then, using the simplex real-time PCR, the A2058G mutation was identified in the Mpn-3655 clinical sample and confirmed by both sequence analysis and macrolide MIC values. With the simplex real-time PCR, the Mpn-3927 specimen produced a T m lower than that of the A2058G control strain, suggesting that the A2058G transition was not present in this sample. The A2059G transition was identified by sequencing analysis and confirmed by MIC studies for the corresponding isolate MP-3996 (Table 2 ). Concerning the Mpn-4276 clinical sample, two melting peaks were observed with the duplex real-time PCR, one with a T m corresponding to a wild-type strain and one with a T m corresponding to an A2058G or A2059G mutation (Table 2) . With the simplex real-time PCR, two melting peaks were also observed, one showing the presence of the A2058G mutation and the other showing a lower T m . Analysis of the 23S rRNA sequence of the corresponding isolate MP-4391 showed a mixture of bases A and G at position 2058, suggesting that wildtype and mutated M. pneumoniae populations could be present in the same sample. Eight subcultured clones obtained from the MP-4391 isolate only harboured the A2058G mutation.
Among 67 clinical specimens, for which only the diagnostic real-time PCR was positive for M. pneumoniae, 21 failed to amplify with the duplex real-time PCR while 44 showed a susceptible genotype. Two clinical specimens, Mpn-4293 and Mpn-4294, harboured a macrolide-resistant genotype. A mutation at position 2611 was found for the Mpn-4293 bronchial aspirate specimen ( Table 2 ). The sequencing analysis from this sample identified the C2611G transition. An A-to-G mutation, either at position 2058 or 2059, was detected for the Mpn-4294 clinical specimen with the duplex real-time PCR and the A2058G transition was identified using the simplex real-time PCR.
To summarize, among 106 M. pneumoniae PCR-positive clinical samples collected over the last decade, 77 were amplified with the duplex real-time PCR, showing that the sensitivity of our assay was 72.6% (77/106). Among them, a resistant genotype was detected for five specimens, that is to say a frequency of 6.5% (5/77). These five specimens were collected between 2005 and 2007 and represented 9.8% (5/51) of the 51 M. pneumoniae-positive clinical samples amplified with our duplex real-time PCR during this period.
Discussion
Respiratory tract infections caused by M. pneumoniae are empirically treated with macrolides. However, recent reports indicate that macrolide-resistant M. pneumoniae isolates are spreading, which could modify the therapeutic management of M. pneumoniae infections. 6, 13 In M. pneumoniae, macrolide resistance is associated in vivo with point mutations in domain V of the 23S rRNA gene at positions 2058, 2059 and 2611. 3 Currently, except sequencing analysis, few technologies have been developed to detect resistance-associated mutations. Concerning M. pneumoniae, only a RFLP method 4 and, recently, a real-time PCR followed by HRM curve analysis were reported to detect A-to-G substitution at position 2058 or 2059. 11 However, sequencing the 23S rRNA gene remained necessary to identify the substitution and only those two mutations were reported to be detected with this technology. In our study, we describe a duplex real-time PCR for the detection of at least six point mutations associated in vivo or in vitro with macrolide resistance in M. pneumoniae. This method was applied directly on clinical samples. Two probe sets were designed for multiplex analysis of the two mutation regions in the M. pneumoniae 23S rRNA gene. As the nucleotide environment of 2058, 2059 and 2062 positions was very rich in guanine and cytosine bases and as mutations were situated in a region with many high-binding secondary structures, it was difficult to design probes compatible with a FRET technology. Consequently, the design of the probes was handmade as software usually used to design real-time assays produced no convincing results. Primers and probes were chosen to be specific for the M. pneumoniae species. For this purpose, the R4-Mpn primer was designed downstream of the 23S rRNA gene, in the 23S -5S intergenic space. Their specificity was confirmed since no positive reaction was obtained with M. pneumoniae-negative samples or with a range of bacteria usually present in respiratory tract samples.
Our assay allowed the detection of the A2058G and A2059G transitions, but their distinction was difficult because of the close proximity of their respective T m s. As the A2058G mutation is involved in 90% of cases of macrolide-resistance in M. pneumoniae, 4 -6 we developed an additional simplex realtime PCR, using the same technology, to accurately identify this transition in clinical specimens.
It should be noted that our assays were less sensitive than the in-house diagnostic real-time PCR performed at the Pellegrin Hospital laboratory for M. pneumoniae detection in clinical specimens. Indeed, among the 106 samples with a positive in-house diagnostic real-time PCR, 29 (27.4%) failed to amplify. This could be due to a difference in the target gene between the two techniques. The present methods target the 23S rRNA gene, which occurs in only one copy in the M. pneumoniae genome, 14 while the in-house diagnostic real-time PCR targets the P1 adhesin gene, which is present in 8-10 copies. 9 The HRM technology also reported a limited sensitivity to detect point mutations associated with macrolide resistance in M. pneumoniae, as seven patient specimens failed to amplify among 30 PCR-and serologyconfirmed M. pneumoniae cases.
11 Thus, our real-time PCR assays should be used secondarily, on clinical samples for which the diagnostic real-time PCR would be positive.
Before 2000, very few macrolide-resistant M. pneumoniae isolates had been reported worldwide. 3 Resistance to MLSKs was reported in 2000 and spread rapidly in Japan, with 30.6% (37/121 strains) resistant isolates described in 2006. 6 In a recent M. pneumoniae outbreak in the USA, 27% (3/11) of isolates harboured a macrolide-resistant genotype. 11 In France, only two macrolide-resistant isolates were reported in 1999 among 155 collected between 1994 and 2006. 9 In our study, among 51 specimens amplified with our duplex real-time PCR and collected between 2005 and 2007, 9.8% (5/51) yielded a M. pneumoniae resistant genotype, suggesting a recent increase of macrolide-resistant M. pneumoniae. This could also be due to a better sensitivity of our genotype-based technique over phenotypebased methods, which require strain isolation by culture before in vitro susceptibility testing. Indeed, a M. pneumoniae isolate was obtained from three of the five macrolide-resistant clinical samples (Table 2) . MLSK susceptibility testing was more fastidious for these three isolates than for the macrolide-susceptible strains. In agar medium, these isolates grew more slowly than the control strain, yielding tiny and uncharacteristic colonies (data not shown). These isolates were wrongly considered as susceptible to MLSKs when the routine susceptibility testing was first realized.
As suggested for other bacterial species, in M. pneumoniae a fitness cost could be connected with macrolide resistanceassociated mutations in the 23S rRNA gene 15 and could explain these data. Indeed, it was reported that clarithromycin-resistant H. pylori isolates, harbouring the A2058G or the A2059G mutation, had a decreased fitness compared with wild-type isolates. 16 This emphasizes the importance of developing genotypic techniques to identify M. pneumoniae resistant isolates.
In our study, among the five patients infected with a macrolide-resistant M. pneumoniae isolate, four of them received a macrolide as the first antimicrobial treatment (Table 2 ). For all of them, the initially prescribed treatment was changed to another MLSK antibiotic, spiramycin, telithromycin or pristinamycin. In agreement with these observations, it was reported that patients infected with macrolide-resistant M. pneumoniae isolates were shown to have the initially prescribed macrolide treatment more frequently changed to another antimicrobial agent, e.g. minocycline or levofloxacin. 6, 13 In our study, neither tetracyclines nor fluoroquinolones were prescribed when antimicrobial change occurred as these antibiotics are not recommended in children. It should be noted that the five patients ultimately recovered.
In M. genitalium, an urogenital pathogen phylogenetically close to M. pneumoniae, macrolide-resistant isolates harbouring mutations at position 2058 or 2059 were associated with treatment failure. 17 In the majority of cases, drug-resistant mutants were selected during macrolide treatment. In our study, as clinical samples collected before treatment were not available for the five patients infected with macrolide-resistant M. pneumoniae, it was not possible to assess this hypothesis.
M. pneumoniae infections commonly occur in children and young adults. In our series, 17 clinical samples were collected from adults (16%). Among them, one macrolide-resistant M. pneumoniae was detected in a 33-year-old man. To our knowledge this is the first description of a macrolide-resistant M. pneumoniae in an adult. Although the majority of studies were conducted in paediatric specimens, 4, 5 it was reported that no macrolide-resistant M. pneumoniae had been observed among 30 isolates from adult patients with community-acquired pneumonia. 6 Therefore, it would be of interest to include adults in a global surveillance for the occurrence of macrolide-resistant M. pneumoniae.
In conclusion, we have developed two real-time PCR assays: a duplex real-time PCR for the detection of the 23S rRNA point mutations associated with clinical macrolide resistance in M. pneumoniae and a simplex real-time PCR for the identification of the A2058G mutation, the most common mutation, both directly applicable to clinical samples. The system of anchor and sensor probes used in these assays is able to discriminate all the genotypes in one reaction, contributing to the rapidity of the method. According to the results of these assays on clinical specimens, we have observed that macrolide resistance of M. pneumoniae is increasing in France, as 9.8% of resistant genotypes were detected between 2005 and 2007. Thus, epidemiological monitoring of M. pneumoniae macrolide-resistant genotypes in clinical specimens has become necessary in Europe, in children as well as in adults. In addition, the rapid determination of the M. pneumoniae genotypic resistance profile to MLSKs could allow the prompt prescription of an alternative antimicrobial treatment if a macrolide-resistant strain is detected.
